|
HRS9531
HRS9531 is an experimental GLP-1 and GIPR The gastric inhibitory polypeptide receptor (GIP-R), also known as the glucose-dependent insulinotropic polypeptide receptor, is a protein that in humans is encoded by the ''GIPR'' gene. GIP-R is a member of the class B family of G protein� ... dual agonist developed by Jiangsu Hengrui. References {{reflist Drugs developed by Jiangsu Hengrui ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
GLP-1 Receptor Agonist
Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP-1RAs, or incretin mimetics, are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. They mimic the actions of the endogenous incretin hormone GLP-1, which is released by the gut after eating. GLP-1 agonists were initially developed for type 2 diabetes. The 2022 American Diabetes Association standards of medical care recommend GLP-1 agonists as a first-line therapy for type 2 diabetes, specifically in patients with atherosclerotic cardiovascular disease or obesity. The drugs were also noted to reduce food intake and body weight significantly, and some have been approved to treat obesity and other components of the metabolic syndrome in the absence of diabetes. They are also in development for other indications, such as non-alcoholic fatty liver disease, polycystic ovary syndrome, and diseases of the reward system such as addictions. Mechanism of ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
GIPR
The gastric inhibitory polypeptide receptor (GIP-R), also known as the glucose-dependent insulinotropic polypeptide receptor, is a protein that in humans is encoded by the ''GIPR'' gene. GIP-R is a member of the class B family of G protein–coupled receptor, G protein coupled receptors. GIP-R is found on beta-cells in the pancreas where it serves as the receptor for the hormone Gastric inhibitory polypeptide (GIP). Function Gastric inhibitory polypeptide, also called glucose-dependent insulinotropic polypeptide, is a 42-amino acid polypeptide synthesized by K cells of the duodenum and small intestine. It was originally identified as an activity in gut extracts that inhibited gastric acid secretion and gastrin release, but subsequently was demonstrated to stimulate insulin release potently in the presence of elevated glucose. The insulinotropic effect on pancreatic islet beta-cells was then recognized to be the principal physiologic action of GIP. Together with glucagon-li ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
GLP1 Poly-agonist Peptides
GLP1 poly-agonist peptides are a class of drugs that activate multiple peptide hormone receptors including the glucagon-like peptide-1 (GLP-1) receptor. These drugs are developed for the same indications as GLP-1 receptor agonists—especially obesity, type 2 diabetes, and non-alcoholic fatty liver disease. They are expected to provide superior efficacy with fewer adverse effects compared to GLP-1 mono-agonists, which are dose-limited by gastrointestinal disturbances. The effectiveness of multi-receptor agonists could possibly equal or exceed that of bariatric surgery. The first such drug to receive approval is tirzepatide, a dual agonist of GLP-1 and GIP receptors. GLP-1 and GIP receptor dual agonists Tirzepatide, a dual agonist of GLP-1 and GIP receptors, is approved for type 2 diabetes and obesity. With an average 20 percent weight loss at a high dosage, it appears to be more effective than GLP-1 mono agonists although there have been no head to head trials as of 2023. GLP-1 and ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Jiangsu Hengrui
Jiangsu Hengrui Pharmaceuticals Company Ltd. (), also known as Jiangsu Hengrui (), is a Chinese pharmaceutical company that manufactures and distributes various types of drug packaging materials, cancer-treating antineoplastics, cardiovascular medication, painkillers, antibiotics, and related products. It is the largest listed pharmaceutical company in China. History Founded in 1970, Jiangsu Hengrui Pharmaceuticals was originally state-owned and called Lianyungang Pharmaceutical Factory (). Headquartered in Lianyungang, Jiangsu, it was established in its current form in 1977. The company was listed on the Shanghai Stock Exchange in 2000 and now has locations in China, the United States, Germany, Switzerland, Japan, and Australia. Research and development In 2020, Jiangsu Hengrui Pharmaceuticals set up research and development offices in Princeton, New Jersey, and in Basel, Switzerland. The Swiss-based Hengrui Europe Therapeutics AG also hosts the discovery research and dev ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |